BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 28069548)

  • 21. Effects of Twist1 on drug resistance of chronic myeloid leukemia cells through the PI3K/AKT signaling pathway.
    Yuan R; Chang J; He J
    Cell Mol Biol (Noisy-le-grand); 2020 Sep; 66(6):81-85. PubMed ID: 33040790
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long non-coding RNA HULC promotes proliferation, migration and invasion of pancreatic cancer cells by down-regulating microRNA-15a.
    Feng H; Wei B; Zhang Y
    Int J Biol Macromol; 2019 Apr; 126():891-898. PubMed ID: 30593805
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 24. LncRNA AB073614 regulates proliferation and metastasis of colorectal cancer cells via the PI3K/AKT signaling pathway.
    Wang Y; Kuang H; Xue J; Liao L; Yin F; Zhou X
    Biomed Pharmacother; 2017 Sep; 93():1230-1237. PubMed ID: 28738539
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pro-Angiogenic Role of LncRNA HULC in Microvascular Endothelial Cells via Sequestrating miR-124.
    Yin D; Li Y; Fu C; Feng Y
    Cell Physiol Biochem; 2018; 50(6):2188-2202. PubMed ID: 30415256
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Down-regulation of Thanatos-associated protein 11 by BCR-ABL promotes CML cell proliferation through c-Myc expression.
    Nakamura S; Yokota D; Tan L; Nagata Y; Takemura T; Hirano I; Shigeno K; Shibata K; Fujisawa S; Ohnishi K
    Int J Cancer; 2012 Mar; 130(5):1046-59. PubMed ID: 21400515
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selective and effective targeting of chronic myeloid leukemia stem cells by topoisomerase II inhibitor etoposide in combination with imatinib mesylate in vitro.
    Liu MY; Wang WZ; Liao FF; Wu QQ; Lin XH; Chen YH; Cheng L; Jin XB; Zhu JY
    Cell Biol Int; 2017 Jan; 41(1):16-23. PubMed ID: 27677634
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TRIM22 knockdown suppresses chronic myeloid leukemia via inhibiting PI3K/Akt/mTOR signaling pathway.
    Li L; Qi Y; Ma X; Xiong G; Wang L; Bao C
    Cell Biol Int; 2018 Sep; 42(9):1192-1199. PubMed ID: 29762880
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Upregulation of miR-181c inhibits chemoresistance by targeting ST8SIA4 in chronic myelocytic leukemia.
    Zhao L; Li Y; Song X; Zhou H; Li N; Miao Y; Jia L
    Oncotarget; 2016 Sep; 7(37):60074-60086. PubMed ID: 27527856
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 2-Methoxyestradiol combined with ascorbic acid facilitates the apoptosis of chronic myeloid leukemia cells via the microRNA-223/Fms-like tyrosine kinase 3/phosphatidylinositol-3 kinase/protein kinase B axis.
    Zhang S; Yu H; Li J; Fan J; Chen J
    Bioengineered; 2022 Feb; 13(2):3470-3485. PubMed ID: 35068331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Local Anesthetic Drug Inhibits Growth and Survival in Chronic Myeloid Leukemia Through Suppressing PI3K/Akt/mTOR.
    Zheng Q; Peng X; Yu H
    Am J Med Sci; 2018 Mar; 355(3):266-273. PubMed ID: 29549929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LncRNA HAND2-AS1 inhibits proliferation and promotes apoptosis of chronic myeloid leukemia cells by sponging with micRNA-1275.
    Yang JR; Shi MX; Zeng Y
    Eur Rev Med Pharmacol Sci; 2019 Mar; 23(5):2103-2111. PubMed ID: 30915755
    [TBL] [Abstract][Full Text] [Related]  

  • 34. α-2,8-Sialyltransferase Is Involved in the Development of Multidrug Resistance via PI3K/Akt Pathway in Human Chronic Myeloid Leukemia.
    Zhang X; Dong W; Zhou H; Li H; Wang N; Miao X; Jia L
    IUBMB Life; 2015 Feb; 67(2):77-87. PubMed ID: 25855199
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impaired immunomodulatory function of chronic myeloid leukemia cancer stem cells and the possible mechanism involved in it.
    Xishan Z; Xinna Z; Baoxin H; Jun R
    Cancer Immunol Immunother; 2013 Apr; 62(4):689-703. PubMed ID: 23180012
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long noncoding RNA myocardial infarction associated transcript promotes the development of thoracic aortic by targeting microRNA-145 via the PI3K/Akt signaling pathway.
    Chen S; Chen H; Yu C; Lu R; Song T; Wang X; Tang W; Gao Y
    J Cell Biochem; 2019 Sep; 120(9):14405-14413. PubMed ID: 30989723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Timosaponin A-III reverses multi-drug resistance in human chronic myelogenous leukemia K562/ADM cells via downregulation of MDR1 and MRP1 expression by inhibiting PI3K/Akt signaling pathway.
    Chen JR; Jia XH; Wang H; Yi YJ; Wang JY; Li YJ
    Int J Oncol; 2016 May; 48(5):2063-70. PubMed ID: 26984633
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-Cancer Role of Dendrosomal Nano Solanine in Chronic Myelogenous Leukemia Cell Line through Attenuation of PI3K/AKT/mTOR Signaling Pathway and Inhibition of hTERT Expression.
    Asgaritarghi G; Farsani SSM; Sadeghizadeh D; Najafi F; Sadeghizadeh M
    Curr Mol Pharmacol; 2023 Mar; 16(5):592-608. PubMed ID: 35578888
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of autophagy enhances the selective anti-cancer activity of tigecycline to overcome drug resistance in the treatment of chronic myeloid leukemia.
    Lu Z; Xu N; He B; Pan C; Lan Y; Zhou H; Liu X
    J Exp Clin Cancer Res; 2017 Mar; 36(1):43. PubMed ID: 28283035
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Downregulation of γ-catenin inhibits CML cell growth and potentiates the response of CML cells to imatinib through β-catenin inhibition.
    Niu CC; Zhao C; Yang ZD; Zhang XL; Wu WR; Pan J; Zhao C; Li ZQ; Ding W; Yang Z; Si WK
    Int J Mol Med; 2013 Feb; 31(2):453-8. PubMed ID: 23233089
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.